Literature DB >> 10488188

Evidence from molecular fingerprinting of limited spread of drug-resistant tuberculosis in Texas.

R W Wilson1, Z Yang, M Kelley, M D Cave, J M Pogoda, R J Wallace, J P Cegielski, D F Dunbar, D Bergmire-Sweat, L B Elliott, P F Barnes.   

Abstract

To determine the contribution of recent transmission to spread of drug-resistant tuberculosis in Texas, we performed IS6110-based and pTBN12-based restriction fragment length polymorphism (RFLP) analyses on Mycobacterium tuberculosis isolates. Isolates collected from 201 patients in Texas between 1992 and 1994 were studied. The distribution of cases was strikingly focal. All cases were reported from 35 of the 254 counties in Texas, and 74% (148 of 201) were reported from only 9 counties. One hundred sixty-one (80%) of the patients had M. tuberculosis isolates with unique RFLP patterns, and 41 (20%) patients were in 20 clusters, each comprising 2 to 3 patients. The largest number of cases of drug-resistant tuberculosis were reported in counties bordering Mexico, but the percentage of clustered cases was highest in northeast Texas and in counties that included the cities of Dallas, Fort Worth, and Houston. Compared to nonclustered patients, clustered patients were more likely to be African American and to have been born in the United States. Clustered patients were significantly more likely to be from the same geographic area, and clustered patients from the same geographic area were more likely to have isolates with identical drug susceptibility patterns, suggesting that they were linked by recent transmission. In 11 of 20 clusters, clustered patients were from geographically separate regions, and most isolates did not have identical drug susceptibility patterns, suggesting that tuberculosis was contracted from a common source in the remote past. Based on the low percentage of clustered cases and the small cluster size, we conclude that there is no evidence for the extensive transmission of drug-resistant tuberculosis in Texas.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10488188      PMCID: PMC85543          DOI: 10.1128/JCM.37.10.3255-3259.1999

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  19 in total

1.  Some observations on the pathogenicity of isoniazid-resistant variants of tubercle bacilli.

Authors:  G MIDDLEBROOK; M L COHN
Journal:  Science       Date:  1953-09-11       Impact factor: 47.728

2.  Patterns of tuberculosis transmission in Central Los Angeles.

Authors:  P F Barnes; Z Yang; S Preston-Martin; J M Pogoda; B E Jones; M Otaya; K D Eisenach; L Knowles; S Harvey; M D Cave
Journal:  JAMA       Date:  1997-10-08       Impact factor: 56.272

3.  Identification of mycobacteria by high-performance liquid chromatography.

Authors:  W R Butler; K C Jost; J O Kilburn
Journal:  J Clin Microbiol       Date:  1991-11       Impact factor: 5.948

4.  Strain identification of Mycobacterium tuberculosis by DNA fingerprinting: recommendations for a standardized methodology.

Authors:  J D van Embden; M D Cave; J T Crawford; J W Dale; K D Eisenach; B Gicquel; P Hermans; C Martin; R McAdam; T M Shinnick
Journal:  J Clin Microbiol       Date:  1993-02       Impact factor: 5.948

5.  Evaluation of method for secondary DNA typing of Mycobacterium tuberculosis with pTBN12 in epidemiologic study of tuberculosis.

Authors:  Z Yang; F Chaves; P F Barnes; W J Burman; J Koehler; K D Eisenach; J H Bates; M D Cave
Journal:  J Clin Microbiol       Date:  1996-12       Impact factor: 5.948

6.  Effects of overexpression of the alkyl hydroperoxide reductase AhpC on the virulence and isoniazid resistance of Mycobacterium tuberculosis.

Authors:  B Heym; E Stavropoulos; N Honoré; P Domenech; B Saint-Joanis; T M Wilson; D M Collins; M J Colston; S T Cole
Journal:  Infect Immun       Date:  1997-04       Impact factor: 3.441

7.  Transmission of tuberculosis in New York City. An analysis by DNA fingerprinting and conventional epidemiologic methods.

Authors:  D Alland; G E Kalkut; A R Moss; R A McAdam; J A Hahn; W Bosworth; E Drucker; B R Bloom
Journal:  N Engl J Med       Date:  1994-06-16       Impact factor: 91.245

8.  An outbreak of multidrug-resistant tuberculosis among hospitalized patients with the acquired immunodeficiency syndrome.

Authors:  B R Edlin; J I Tokars; M H Grieco; J T Crawford; J Williams; E M Sordillo; K R Ong; J O Kilburn; S W Dooley; K G Castro
Journal:  N Engl J Med       Date:  1992-06-04       Impact factor: 91.245

9.  The epidemiology of tuberculosis in San Francisco. A population-based study using conventional and molecular methods.

Authors:  P M Small; P C Hopewell; S P Singh; A Paz; J Parsonnet; D C Ruston; G F Schecter; C L Daley; G K Schoolnik
Journal:  N Engl J Med       Date:  1994-06-16       Impact factor: 91.245

10.  Effect of inhA and katG on isoniazid resistance and virulence of Mycobacterium bovis.

Authors:  T M Wilson; G W de Lisle; D M Collins
Journal:  Mol Microbiol       Date:  1995-03       Impact factor: 3.501

View more
  8 in total

1.  Characterization of ancestral Mycobacterium tuberculosis by multiple genetic markers and proposal of genotyping strategy.

Authors:  Yong-Jiang Sun; Ann S G Lee; Sze Ta Ng; Sindhu Ravindran; Kristin Kremer; Richard Bellamy; Sin-Yew Wong; Dick van Soolingen; Philip Supply; Nicholas I Paton
Journal:  J Clin Microbiol       Date:  2004-11       Impact factor: 5.948

2.  Antibiotic resistance and single-nucleotide polymorphism cluster grouping type in a multinational sample of resistant Mycobacterium tuberculosis isolates.

Authors:  M Brimacombe; M Hazbon; A S Motiwala; D Alland
Journal:  Antimicrob Agents Chemother       Date:  2007-09-10       Impact factor: 5.191

3.  Population genetics study of isoniazid resistance mutations and evolution of multidrug-resistant Mycobacterium tuberculosis.

Authors:  Manzour Hernando Hazbón; Michael Brimacombe; Miriam Bobadilla del Valle; Magali Cavatore; Marta Inírida Guerrero; Mandira Varma-Basil; Helen Billman-Jacobe; Caroline Lavender; Janet Fyfe; Lourdes García-García; Clara Inés León; Mridula Bose; Fernando Chaves; Megan Murray; Kathleen D Eisenach; José Sifuentes-Osornio; M Donald Cave; Alfredo Ponce de León; David Alland
Journal:  Antimicrob Agents Chemother       Date:  2006-08       Impact factor: 5.191

4.  Spread of drug-resistant pulmonary tuberculosis in Estonia.

Authors:  A Krüüner; S E Hoffner; H Sillastu; M Danilovits; K Levina; S B Svenson; S Ghebremichael; T Koivula; G Källenius
Journal:  J Clin Microbiol       Date:  2001-09       Impact factor: 5.948

5.  Role of embB codon 306 mutations in Mycobacterium tuberculosis revisited: a novel association with broad drug resistance and IS6110 clustering rather than ethambutol resistance.

Authors:  Manzour Hernando Hazbón; Miriam Bobadilla del Valle; Marta Inírida Guerrero; Mandira Varma-Basil; Ingrid Filliol; Magali Cavatore; Roberto Colangeli; Hassan Safi; Helen Billman-Jacobe; Caroline Lavender; Janet Fyfe; Lourdes García-García; Amy Davidow; Michael Brimacombe; Clara Inés León; Tania Porras; Mridula Bose; Fernando Chaves; Kathleen D Eisenach; José Sifuentes-Osornio; Alfredo Ponce de León; M Donald Cave; David Alland
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

6.  Transmission of drug-resistant tuberculosis in Texas and Mexico.

Authors:  Teresa N Quitugua; Barbara J Seaworth; Stephen E Weis; Jeffery P Taylor; J Seb Gillette; Ishmael I Rosas; Kenneth C Jost; D Mitchel Magee; Rebecca A Cox
Journal:  J Clin Microbiol       Date:  2002-08       Impact factor: 5.948

7.  The epidemiological fitness cost of drug resistance in Mycobacterium tuberculosis.

Authors:  Fabio Luciani; Scott A Sisson; Honglin Jiang; Andrew R Francis; Mark M Tanaka
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-13       Impact factor: 11.205

8.  Molecular diversity of drug resistant mycobacterium tuberculosis strains in Western Turkey.

Authors:  Süheyla Sürücüoğlu; Selami Günal; Nuri Ozkütük; Can Biçmen; Ayşe Ozsöz; Hörü Gazi; Rıza Durmaz
Journal:  Balkan Med J       Date:  2012-06-01       Impact factor: 2.021

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.